Acyclovir (Systemic)

Brand names: Zovirax
Drug class: Antineoplastic Agents

Usage of Acyclovir (Systemic)

Mucocutaneous, Ocular, and Systemic Herpes Simplex Virus (HSV) Infections

Treatment of initial and recurrent mucocutaneous HSV-1 and HSV-2 infections (e.g., orofacial, esophageal, genital, nasal, labial) in immunocompromised adults, adolescents, and children, including HIV-infected individuals. Drug of choice.

Chronic suppressive or maintenance therapy (secondary prophylaxis) of recurrent HSV infections† [off-label] in immunocompromised adults, adolescents, and children, including HIV-infected individuals who have frequent or severe recurrences.

Treatment of orolabial HSV infections (including gingivostomatitis) in immunocompetent† [off-label] adults and children; generally ineffective or minimally effective for prevention of recurrence of herpes labialis† [off-label] in immunocompetent individuals.

Treatment of eczema herpeticum† [off-label] in patients with a history of atopic dermatitis.

Treatment of HSV keratitis† [off-label] in HIV-infected patients.

Prophylaxis against recurrence of ocular HSV disease† in immunocompetent adults and children ≥12 years of age who had ocular HSV disease (blepharitis, conjunctivitis, epithelial keratitis, stromal keratitis, iritis) in one or both eyes within the preceding 12 months. Has been used for prophylaxis after penetrating keratoplasty for herpetic keratitis.

Drug of choice for treatment of HSV encephalitis.

Drug of choice for treatment of neonatal HSV infections, including mucocutaneous infections, infections involving skin, eyes, and mouth, and disseminated or CNS infections.

Drug of choice for prevention of HSV recurrence† in hematopoietic stem cell transplant (HSCT) recipients seropositive for HSV; such prophylaxis not indicated in those seronegative for HSV.

Genital Herpes

Treatment of initial episodes of genital herpes in adults and adolescents, including HIV-infected individuals.

Treatment of first episodes of herpes proctitis†.

Episodic treatment of recurrent episodes of genital herpes in adults and adolescents, including HIV-infected individuals.

Chronic suppressive therapy of recurrent episodes of genital herpes in adults and adolescents, including HIV-infected individuals.

CDC and others recommend oral acyclovir, oral famciclovir, or oral valacyclovir as drugs of choice for treatment of initial episodes of genital herpes and for episodic treatment or chronic suppressive therapy of recurrent genital herpes.

Varicella-Zoster Infections

Treatment of varicella (chickenpox) in immunocompromised adults, adolescents, and children, including HIV-infected individuals. Drug of choice.

Treatment of varicella (chickenpox) in immunocompetent adults, adolescents, and children. Varicella usually is a self-limited disease in otherwise healthy individuals and the role of acyclovir for treatment in these individuals is controversial; routine use not recommended by AAP and other clinicians.

Treatment of herpes zoster (shingles, zoster) in immunocompetent or immunocompromised adults, adolescents, and children, including HIV-infected individuals. Drug of choice for serious or disseminated herpes zoster in immunocompromised patients.

Treatment of herpes zoster ophthalmicus† in HIV-infected patients.

Treatment of dermatomal herpes zoster in immunocompromised patients† including transplant recipients and HIV-infected patients.

Alternative to varicella-zoster immune globulin (VZIG) for postexposure prophylaxis of VZV infection† in HSCT recipients. Although long-term prophylaxis not routinely recommended for prevention of recurrent VZV infections in HSCT recipients, such prophylaxis may be considered in those with severe, long-term immunodeficiency.

Prevention of Cytomegalovirus (CMV) Disease in Transplant Recipients

Has been used for prevention of CMV disease† in solid organ transplant recipients and bone marrow transplant (BMT) recipients at risk for the disease; data regarding efficacy are conflicting.

Has been used for prevention of CMV disease† in HSCT recipients; generally ineffective after autologous HSCT. Ganciclovir is drug of choice for prevention of CMV following autologous or allogeneic HSCT in adults, adolescents, and children.

Not effective for prevention of CMV disease in HIV-infected individuals.

Epstein-Barr Virus Infections and Disorders

Treatment of uncomplicated or complicated infectious mononucleosis, chronic infectious mononucleosis, and various disorders (e.g., oral hairy leukoplakia) associated with Epstein-Barr virus infections†; efficacy appears to be variable.

Relate drugs

How to use Acyclovir (Systemic)

Administration

Administer orally or by IV infusion.

Parenteral preparation should not be administered orally or by IM or sub-Q injection and should not be applied topically or to the eye.

Oral Administration

Administer without regard to meals.

IV Infusion

For solution and drug compatibility information, see Compatibility under Stability.

Reconstitution

Reconstitute vial containing 500 mg or 1 g of acyclovir powder with 10 or 20 mL of sterile water for injection, respectively, to provide a solution containing 50 mg/mL.

Shake well to ensure complete dissolution. Must be diluted further before IV administration.

Dilution

For IV infusion, dilute concentrate containing acyclovir 25 or 50 mg/mL with a compatible IV solution (see Solution Compatibility under Stability) to a concentration of ≤7 mg/mL.

Alternatively, dilute solutions reconstituted from powder prior to IV infusion with 50–125 mL of a compatible IV infusion solution. (See Solution Compatibility under Stability.) For fluid-restricted patients, dilute reconstituted solution in a ratio of approximately 1 part reconstituted solution to 9 parts infusion solution to a concentration of ≤7 mg/mL.

Rate of Administration

Administer by IV infusion at a constant rate over at least 1 hour. Do not administer by rapid IV infusion (over <10 minutes) or rapid IV injection. (See Renal Effects under Cautions.)

Ensure adequate hydration.

Dosage

Available as acyclovir and acyclovir sodium; dosage expressed in terms of acyclovir.

Pediatric Patients

Mucocutaneous, Ocular, and Systemic Herpes Simplex Virus (HSV) Infections Treatment of Mucocutaneous HSV Infections Oral†

Immunocompromised children: 1 g daily given in 3–5 divided doses for 7–14 days.

IV

Immunocompromised children <12 years of age: 10 mg/kg every 8 hours for 7–14 days.

HIV-infected or immunocompromised adolescents and children ≥12 years of age: 5 mg/kg every 8 hours for 7–14 days. Alternatively, after lesions begin to regress, consider switching to oral acyclovir in a dosage of 400 mg 3 times daily and continue until lesions are completely healed.

HSV Gingivostomatitis Oral†

HIV-infected children with mild, symptomatic gingivostomatitis: CDC and others recommend 20 mg/kg (up to 400 mg) 3 times daily for 7–14 days.

Immunocompetent children: 15 mg/kg (up to 200 mg) 5 times daily for 7 days has been used in a few children 1–6 years of age.

IV

HIV-infected children with moderate to severe gingivostomatitis: CDC and others recommend 5–10 mg/kg 3 times daily for 7–14 days. Consider chronic oral suppressive or maintenance therapy (secondary prophylaxis) in those with frequent or severe recurrences of gingivostomatitis.

Chronic Suppressive or Maintenance Therapy (Secondary Prophylaxis) of HSV Infections† Oral

HIV-infected infants and children: 80 mg/kg daily (up to 1 g daily) in 3 or 4 divided doses.

HIV-infected adolescents: 200 mg 3 times daily or 400 mg twice daily.

Prophylaxis Against Recurrent Ocular HSV Disease† Oral

Children ≥12 years of age: 400 mg twice daily. AAP recommends 80 mg/kg daily (up to 1 g daily) given in 3 divided doses.

Optimum duration of prophylaxis unclear; has been continued for 12–18 months in clinical studies.

Treatment of HSV Encephalitis or Disseminated Disease IV

Immunocompromised children: 20 mg/kg every 8 hours in those 3 months to 12 years of age and 10–15 mg/kg every 8 hours in those ≥12 years of age. Manufacturer recommends a treatment duration of 10 days, but AAP and others recommend 14–21 days for disseminated or CNS infections.

HIV-infected children: CDC and others recommend 10 mg/kg or 500 mg/m2 3 times daily for 21 days.

HIV-infected adolescents: CDC and others recommend 10 mg/kg 3 times daily for 14–21 days.

Treatment of Neonatal HSV Infections IV

Neonates and children ≤3 months of age: Manufacturer recommends 10 mg/kg every 8 hours for 10 days.

Neonates and children ≤3 months of age: AAP recommends 20 mg/kg every 8 hours given for 14 days for infections of skin, eyes, or mouth or 21 days for disseminated or CNS infections.

HIV-infected or -exposed neonates: CDC and others recommend 20 mg/kg 3 times daily given for 14 days for infections of skin, eyes, or mouth or 21 days for disseminated or CNS infections.

Prevention of HSV Recurrence in Hematopoietic Stem Cell Transplant (HSCT) Recipients† Oral

HSV-seropositive children: 0.6–1 g daily given in 3–5 divided doses.

HSV-seropositive adolescents: 200 mg 3 times daily.

Initiate prophylaxis at beginning of conditioning therapy and continue until engraftment or until mucositis resolves (approximately 30 days after allogeneic HSCT). Routine prophylaxis for >30 days after HSCT not recommended.

IV

HSV-seropositive children: 250 mg/m2 every 8 hours or 125 mg/m2 every 6 hours.

HSV-seropositive adolescents: 250 mg/m2 every 12 hours.

Initiate prophylaxis at beginning of conditioning therapy and continue until engraftment or until mucositis resolves (approximately 30 days after allogeneic HSCT). Routine prophylaxis for >30 days after HSCT not recommended.

Genital Herpes Treatment of First Episodes Oral

Children: AAP recommends 40–80 mg/kg daily (maximum 1 g daily) given in 3 or 4 divided doses for 5–10 days.

Adolescents: CDC recommends 400 mg 3 times daily or 200 mg 5 times daily for 7–10 days; duration may be extended if healing is incomplete after 10 days.

HIV-infected adolescents: CDC and others recommend 20 mg/kg (up to 400 mg) or 400 mg 3 times daily for 7–14 days.

IV

Adolescents and children ≥12 years of age with severe initial episodes: 5–10 mg/kg every 8 hours.

Manufacturer and some clinicians recommend 5–7 days of IV acyclovir; CDC states IV acyclovir should be given for 2–7 days or until clinical improvement occurs, followed by an oral antiviral to complete at least 10 days of treatment.

Episodic Treatment of Recurrent Episodes Oral

Adolescents: CDC recommends 400 mg 3 times daily for 5 days, 800 mg twice daily for 5 days, or 800 mg 3 times daily for 2 days.

HIV-infected adolescents: CDC recommends 400 mg 3 times daily for 5–10 days. Alternatively, acyclovir can be given for 7–14 days.

Initiate episodic therapy at the earliest prodromal sign or symptom of recurrence or within 1 day of the onset of lesions.

Chronic Suppression of Recurrent Episodes Oral

Adolescents: CDC recommends 400 mg twice daily.

HIV-infected adolescents: CDC recommends 400–800 mg 2 or 3 times daily.

Discontinue periodically (e.g., after 12 months or once yearly) to reassess need for continued therapy.

Varicella-Zoster Infections Treatment of Varicella (Chickenpox) Oral

Immunocompetent children ≥2 years of age: Manufacturer recommends 20 mg/kg 4 times daily (maximum 80 mg/kg daily) for 5 days in those weighing ≤40 kg and 800 mg 4 times daily for 5 days in those weighing >40 kg. Alternatively, some clinicians recommend 20 mg/kg (up to 800 mg) 4 times daily for 5 days.

HIV-infected children with mild immunosuppression and mild varicella: CDC and others recommend 20 mg/kg (up to 800 mg) 4 times daily for 7 days or until no new lesions have appeared for 48 hours.

Initiate therapy at the earliest sign or symptom of infection (within 24 hours of onset of rash).

IV

Immunocompromised children: AAP recommends 10 mg/kg 3 times daily for 7–10 days for those <1 year of age and 500 mg/m2 3 times daily for 7–10 days in those ≥1 year of age.

Immunocompromised adolescents and children: Some clinicians recommend 20 mg/kg every 8 hours for 7–10 days in those ≤12 years of age and 10 mg/kg every 8 hours for 7 days in those >12 years of age.

HIV-infected children with moderate or severe immunosuppression and varicella associated with high fever or necrotic lesions: CDC and others recommend 10 mg/kg 3 times daily for 7 days or until no new lesions have appeared for 48 hours. Alternatively, a dosage of 500 mg/m2 every 8 hours has been suggested for those ≥1 year of age.

HIV-infected adolescents: CDC and others recommend 10 mg/kg every 8 hours for 7–10 days. After defervescence and if there is no evidence of visceral involvement, switch to oral acyclovir in a dosage of 800 mg 4 times daily.

Treatment of Herpes Zoster (Shingles, Zoster) Oral

Immunocompetent children ≥12 years of age: 800 mg every 4 hours 5 times daily (4 g daily) for 5–10 days.

HIV-infected children with mild immunosuppression and mild varicella: CDC and others recommend 20 mg/kg (up to 800 mg) 4 times daily for 7–10 days.

Initiate therapy preferably within 48 hours of onset of rash.

IV

Immunocompetent children: AAP recommends 10 mg/kg 3 times daily for 7–10 days for those <1 year of age and 500 mg/m2 3 times daily for 7–10 days in those ≥1 year of age.

Immunocompromised children: 20 mg/kg every 8 hours for 7–10 days in those <12 years of age and 10 mg/kg every 8 hours for 7 days in those ≥12 years of age.

HIV-infected children with severe immunosuppression and extensive multidermatomal zoster or zoster with trigeminal nerve involvement: CDC and others recommend 10 mg/kg 3 times daily for 7–10 days.

HIV-infected adolescents: CDC and others recommend 10 mg/kg every 8 hours until cutaneous and visceral disease resolves.

Adults

Mucocutaneous, Ocular, and Systemic Herpes Simplex Virus (HSV) Infections Treatment of Mucocutaneous HSV Infections Oral†

Immunocompromised or HIV-infected adults: 400 mg every 4 hours while awake (5 times daily) for 7–14 days.

IV

Immunocompromised or HIV-infected adults: CDC and others recommend 5 mg/kg every 8 hours for 7–14 days. Alternatively, after lesions begin to regress, consider switching to oral acyclovir in a dosage of 400 mg 3 times daily and continue until lesions are completely healed.

Chronic Suppressive or Maintenance Therapy (Secondary Prophylaxis) of HSV Infections† Oral

HIV-infected adults: 200 mg 3 times daily or 400 mg twice daily.

Treatment of Orolabial HSV Infections Oral

400 mg 5 times daily for 5 days.

HIV-infected adults: CDC and others recommend 400 mg 3 times daily for 7–14 days.

Treatment of HSV Keratitis† Oral

HIV-infected adults: 400 mg 5 times daily. Long-term therapy may be required to prevent recurrence.

Prophylaxis Against Recurrent Ocular HSV Disease† Oral

Immunocompetent adults: 400 mg twice daily. Optimum duration of prophylaxis unclear; has been continued for 12–18 months in clinical studies.

Treatment of HSV Encephalitis or Disseminated Disease IV

10–15 mg/kg every 8 hours. Manufacturer recommends a treatment duration of 10 days, but CDC and others recommend 14–21 days for disseminated or CNS infections.

HIV-infected adults: CDC and others recommend 10 mg/kg 3 times daily for 14–21 days.

Prevention of HSV Recurrence in Hematopoietic Stem Cell Transplant (HSCT) Recipients† Oral

HSV-seropositive adults: 200 mg 3 times daily initiated at beginning of conditioning therapy and continued until engraftment or until mucositis resolves (i.e., approximately 30 days after allogeneic HSCT). Routine prophylaxis for >30 days after HSCT not recommended.

IV

HSV-seropositive adults: 250 mg/m2 every 12 hours initiated at beginning of conditioning therapy and continued until engraftment or until mucositis resolves (i.e., approximately 30 days after allogeneic HSCT). Routine prophylaxis for >30 days after HSCT not recommended.

Genital Herpes Treatment of First Episodes Oral

Manufacturer recommends 200 mg every 4 hours while awake (5 times daily) for 10 days.

CDC and others recommend 400 mg 3 times daily or 200 mg 5 times daily for 7–10 days; duration may be extended if healing is incomplete after 10 days.

HIV-infected adults: CDC and others recommend 400 mg 3 times daily for 7–14 days.

IV

Adults with severe initial episodes: 5–10 mg/kg every 8 hours.

Manufacturer and some clinicians recommend 5–7 days of IV acyclovir; CDC states IV acyclovir should be given for 2–7 days or until clinical improvement occurs, followed by an oral antiviral to complete at least 10 days of therapy.

Treatment of First Episode of Herpes Proctitis† Oral

400 mg 5 times daily for 10 days or until clinical resolution occurs.

Episodic Treatment of Recurrent Episodes of Genital Herpes Oral

Manufacturer recommends 200 mg every 4 hours while awake (5 times daily) for 5 days.

CDC recommends 400 mg 3 times daily for 5 days, 800 mg twice daily for 5 days, or 800 mg 3 times daily for 2 days.

HIV-infected adults: CDC recommends 400 mg 3 times daily for 5–10 days. Alternatively, acyclovir can be given for 7–14 days.

Initiate episodic therapy at the earliest prodromal sign or symptom of recurrence or within 1 day of the onset of lesions.

Chronic Suppression of Recurrent Episodes of Genital Herpes Oral

400 mg twice daily; alternatively, 200 mg 3–5 times daily.

HIV-infected adults: 400–800 mg 2 or 3 times daily.

Discontinue periodically (e.g., after 12 months or once yearly) to reassess need for continued therapy.

Varicella-Zoster Infections Treatment of Varicella (Chickenpox) Oral

20 mg/kg (up to 800 mg) 4 times daily for 5 days.

Initiate therapy at the earliest sign or symptom of infection (within 24 hours of onset of rash).

IV, then Oral

HIV-infected or immunocompromised adults: CDC and others recommend 10 mg/kg every 8 hours for 7–10 days. After defervescence and if there is no evidence of visceral involvement, switch to oral acyclovir in a dosage of 800 mg 4 times daily.

Treatment of Herpes Zoster (Shingles, Zoster) Oral

800 mg every 4 hours (5 times daily) for 7–10 days.

Initiate therapy preferably within 48 hours of onset of rash.

IV

HIV-infected or immunocompromised adults: CDC and others recommend 10 mg/kg every 8 hours for 7 days or until cutaneous and visceral disease resolves.

Treatment of Herpes Zoster Ophthalmicus† Oral

Immunocompetent adults: 600 mg every 4 hours 5 times daily (3 g daily) for 10 days.

Initiate therapy within 72 hours (but no later than 7 days) after rash onset.

IV, then Oral

HIV-infected adults: 10 mg/kg IV 3 times daily for 7 days followed by 800 mg orally 3–5 times daily has been used.

Treatment of Dermatomal Herpes Zoster† Oral

Immunocompromised adults: 800 mg 5 times daily for 10 days has been used, but CDC and others recommend oral famciclovir or valacyclovir for localized dermal infections in HIV-infected individuals.

Prescribing Limits

Pediatric Patients

Oral

Maximum 20 mg/kg 4 times daily (1 g daily) in children ≥2 years of age weighing ≤40 kg.

IV

Maximum 20 mg/kg every 8 hours.

Adults

Oral

800 mg per dose.

IV

Maximum 20 mg/kg every 8 hours.

Special Populations

Renal Impairment

Adjustment of Usual Oral Dosage Oral Dosage in Renal Impairment403

Usual Dosage Regimen

Clcr (mL/min per 1.73 m2)

Adjusted Dosage Regimen

200 mg every 4 h 5 times daily

>10

No adjustment necessary

0–10

200 mg every 12 h

400 mg every 12 h

>10

No adjustment necessary

0–10

200 mg every 12 h

800 mg every 4 h 5 times daily

>25

No adjustment necessary

10–25

800 mg every 8 h

0–10

800 mg every 12 h

Hemodialysis

Give supplemental oral dose immediately after each dialysis period.

Peritoneal Dialysis

Supplemental doses do not appear necessary.

Adjustment of Usual IV Dosage IV Dosage in Renal Impairment409

Clcr (mL/min per 1.73 m2)

Percent of Recommended Dose

Dosing Interval (hours)

>50

100%

8

25–50

100%

12

10–25

100%

24

0–10

50%

24

Hemodialysis

Adjust dosing schedule so that a supplemental IV dose is administered immediately after each dialysis period.

CAPD

Supplemental doses do not appear necessary.

Alternative IV Dosage Regimens for End-Stage Renal Disease

93–185 mg/m2 as a loading dose, followed by a maintenance dosage of 35–70 mg/m2 every 8 hours, and 56–185 mg/m2 immediately after dialysis.

250–500 mg/m2 as a loading dose, followed by a maintenance dosage of 250–500 mg/m2 every 48 hours, and 150–500 mg/m2 immediately after dialysis.

2.5 mg/kg every 24 hours and 2.5 mg/kg after each dialysis period.

HIV-infected Patients with Impaired Renal Function (Oral Administration) Oral Dosage for HIV-infected Patients with Impaired Renal Function (Based on Usual Dosage of 200–800 mg Every 4–6 Hours)411

Clcr (mL/min per 1.73 m2)

Adjusted Dosage Regimen

>80

No adjustment necessary

50–80

200–800 mg every 6–8 h

25–50

200–800 mg every 8–12 h

10–25

200–800 mg every 12–24 h

<10

200–400 mg every 24 h

Hemodialysis

Give supplemental usual oral dose after each dialysis period.

HIV-infected Patients with Impaired Renal Function (IV Administration) IV Dosage for HIV-infected Patients with Impaired Renal Function (Based on Usual Dosage of 5 mg/kg Every 8 hours)409411

Clcr (mL/min per 1.73 m2)

Adjusted Dosage Regimen

>80

No adjustment necessary

50–80

No adjustment necessary

25–50

5 mg/kg every 12–24 hours

10–25

5 mg/kg every 12–24 hours

<10

2.5 mg/kg every 24 hours

Hemodialysis

Adjust dosing schedule so that daily IV dose is given after hemodialysis on dialysis days.

Geriatric Patients

Cautious dosage selection; reduced dosage may be needed because of age-related decreases in renal function. (See Geriatric Use under Cautions.)

Obese Patients

Use ideal body weight to determine IV dosage.

Warnings

Contraindications

  • Known hypersensitivity to acyclovir or valacyclovir.
  • Warnings/Precautions

    Warnings

    Renal Effects

    Increased BUN and/or Scr, anuria, and hematuria have been reported. Transient increases in BUN and/or Scr and decreases in Clcr reported in patients receiving IV acyclovir, particularly following rapid (over <10 minutes) IV infusion.

    Abnormal urinalysis (increase in formed elements in urine sediment) and pain or pressure on urination reported rarely with IV acyclovir.

    Renal failure, resulting in death, has occurred.

    Possible precipitation of acyclovir in renal tubules, resulting in renal tubular damage and acute renal failure, when the solubility of free acyclovir in the collecting duct is exceeded or following rapid IV administration.

    Risk of adverse renal effects during IV therapy depends on degree of hydration, urine output, concomitant therapy (i.e., nephrotoxic drugs), preexisting renal disease, and rate of administration (see Rate of Administration under Dosage and Administration).

    Alterations in renal function during IV acyclovir therapy can progress to acute renal failure but generally are transient and resolve spontaneously or following improved hydration and electrolyte balance, dosage adjustment, or discontinuance of the drug.

    Hematologic Effects

    Potentially fatal thrombotic thrombocytopenic purpura/hemolytic uremic syndrome reported in immunocompromised patients receiving acyclovir.

    General Precautions

    Nervous System Effects

    Possible encephalopathic effects (e.g., lethargy, obtundation, tremors, confusion, hallucinations, agitation, seizures, coma) in patients receiving IV acyclovir.

    Use with caution in patients with underlying neurologic abnormalities and in those with serious renal, hepatic, or electrolyte abnormalities or substantial hypoxia.

    Local Effects

    Severe local inflammatory reactions, including tissue necrosis, have occurred following infusion of acyclovir into extravascular tissues.

    Sodium Content

    Sodium salt of acyclovir contains 4.2 mEq of sodium per gram of acyclovir.

    Specific Populations

    Pregnancy

    Category B.

    CDC, AAP, and others state that oral acyclovir may be used during pregnancy to treat first episodes or severe recurrent episodes of genital herpes and IV acyclovir may be used during pregnancy to treat severe HSV infection (especially life-threatening disseminated infections). CDC and others also recommend acyclovir for treatment of varicella during pregnancy, particularly during the second and third trimesters.

    Lactation

    Distributed into milk following oral or IV administration. Use with caution.

    Women with active herpetic lesions near or on the breast should refrain from breast-feeding.

    Pediatric Use

    Safety and efficacy of oral acyclovir not established in children <2 years of age.

    Geriatric Use

    For treatment of herpes zoster (shingles, zoster), no substantial differences in efficacy of oral acyclovir relative to younger adults, but duration of pain after healing may be longer in geriatric patients.

    Insufficient experience in patients ≥65 years of age to determine whether geriatric patients respond differently to IV acyclovir than younger adults.

    Select dosage with caution because of age-related decreases in renal function and potential for concomitant disease and drug therapy. Consider monitoring renal function.

    Possible increased incidence of adverse CNS effects (coma, confusion, hallucinations, somnolence), GI effects (nausea, vomiting), or dizziness during oral acyclovir therapy compared with younger adults.

    Hepatic Impairment

    Use with caution.

    Renal Impairment

    Decreased acyclovir clearance. Increased risk of adverse renal and encephalopathic effects.

    Adjust dosage to prevent drug accumulation, decrease risk of toxicity, and maintain adequate plasma drug concentrations. (See Renal Impairment under Dosage and Administration.)

    Common Adverse Effects

    With oral therapy, nausea and/or vomiting and diarrhea. With IV therapy, local reactions at the injection site (inflammation, phlebitis).

    What other drugs will affect Acyclovir (Systemic)

    Nephrotoxic Agents

    Potential pharmacodynamic interaction (increased risk of renal dysfunction and/or reversible CNS manifestations); use concomitantly with caution.

    Specific Drugs

    Drug

    Interaction

    Comments

    Interferon

    Additive or synergistic antiviral effect against HSV-1 in vitro

    Clinical importance unknown; use with caution

    Methotrexate

    Manufacturer states that IV acyclovir should be used with caution in patients receiving intrathecal methotrexate

    Probenecid

    Decreased renal clearance of acyclovir

    Zidovudine

    Neurotoxicity (profound drowsiness, lethargy) reported in at least 1 patient

    Monitor patients closely during concomitant therapy

    Disclaimer

    Every effort has been made to ensure that the information provided by Drugslib.com is accurate, up-to-date, and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. Drugslib.com information has been compiled for use by healthcare practitioners and consumers in the United States and therefore Drugslib.com does not warrant that uses outside of the United States are appropriate, unless specifically indicated otherwise. Drugslib.com's drug information does not endorse drugs, diagnose patients or recommend therapy. Drugslib.com's drug information is an informational resource designed to assist licensed healthcare practitioners in caring for their patients and/or to serve consumers viewing this service as a supplement to, and not a substitute for, the expertise, skill, knowledge and judgment of healthcare practitioners.

    The absence of a warning for a given drug or drug combination in no way should be construed to indicate that the drug or drug combination is safe, effective or appropriate for any given patient. Drugslib.com does not assume any responsibility for any aspect of healthcare administered with the aid of information Drugslib.com provides. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse or pharmacist.

    Popular Keywords

    AI Assitant